Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Rocket Pharmaceuticals stock | $28.97

Learn how to easily invest in Rocket Pharmaceuticals stock.

Rocket Pharmaceuticals Inc is a biotechnology business based in the US. Rocket Pharmaceuticals shares (RCKT) are listed on the NASDAQ and all prices are listed in US Dollars. Rocket Pharmaceuticals employs 91 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Rocket Pharmaceuticals

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – RCKT – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Rocket Pharmaceuticals stock price (NASDAQ: RCKT)

Use our graph to track the performance of RCKT stocks over time.

Rocket Pharmaceuticals shares at a glance

Information last updated 2021-10-18.
Latest market close$28.97
52-week range$26.72 - $67.48
50-day moving average $32.10
200-day moving average $39.01
Wall St. target price$69.78
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.79

Buy Rocket Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Rocket Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Rocket Pharmaceuticals price performance over time

Historical closes compared with the close of $28.97 from 2021-10-21

1 week (2021-10-15) 3.76%
1 month (2021-09-22) -10.67%
3 months (2021-07-22) -40.84%
6 months (2021-04-22) -34.90%
1 year (2020-10-22) 0.56%
2 years (2019-10-22) 105.17%
3 years (2018-10-22) 62.02%
5 years (2016-10-21) 273.81%

Rocket Pharmaceuticals financials

Gross profit TTM $0
Return on assets TTM -22.43%
Return on equity TTM -43.57%
Profit margin 0%
Book value $7.71
Market capitalisation $1.8 billion

TTM: trailing 12 months

Shorting Rocket Pharmaceuticals shares

There are currently 8.1 million Rocket Pharmaceuticals shares held short by investors – that's known as Rocket Pharmaceuticals's "short interest". This figure is 2.4% up from 7.9 million last month.

There are a few different ways that this level of interest in shorting Rocket Pharmaceuticals shares can be evaluated.

Rocket Pharmaceuticals's "short interest ratio" (SIR)

Rocket Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Rocket Pharmaceuticals shares currently shorted divided by the average quantity of Rocket Pharmaceuticals shares traded daily (recently around 398498.57283465). Rocket Pharmaceuticals's SIR currently stands at 20.32. In other words for every 100,000 Rocket Pharmaceuticals shares traded daily on the market, roughly 20320 shares are currently held short.

However Rocket Pharmaceuticals's short interest can also be evaluated against the total number of Rocket Pharmaceuticals shares, or, against the total number of tradable Rocket Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Rocket Pharmaceuticals's short interest could be expressed as 0.13% of the outstanding shares (for every 100,000 Rocket Pharmaceuticals shares in existence, roughly 130 shares are currently held short) or 0.1759% of the tradable shares (for every 100,000 tradable Rocket Pharmaceuticals shares, roughly 176 shares are currently held short).

A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against Rocket Pharmaceuticals.

Find out more about how you can short Rocket Pharmaceuticals stock.

Rocket Pharmaceuticals share dividends

We're not expecting Rocket Pharmaceuticals to pay a dividend over the next 12 months.

Have Rocket Pharmaceuticals's shares ever split?

Rocket Pharmaceuticals's shares were split on a 1:4 basis on 4 January 2018. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Rocket Pharmaceuticals shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Rocket Pharmaceuticals shares which in turn could have impacted Rocket Pharmaceuticals's share price.

Rocket Pharmaceuticals share price volatility

Over the last 12 months, Rocket Pharmaceuticals's shares have ranged in value from as little as $26.7197 up to $67.48. A popular way to gauge a stock's volatility is its "beta".

RCKT.US volatility(beta: 1.55)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Rocket Pharmaceuticals's is 1.5519. This would suggest that Rocket Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Rocket Pharmaceuticals overview

Rocket Pharmaceuticals, Inc. , together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has four clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia; and infantile malignant osteopetrosis, a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO Inc. The company also has a research and collaboration agreement with Lund University; and strategic collaboration agreement with Stanford University School of Medicine. Rocket Pharmaceuticals, Inc.

Frequently asked questions

What percentage of Rocket Pharmaceuticals is owned by insiders or institutions?
Currently 4.562% of Rocket Pharmaceuticals shares are held by insiders and 100.113% by institutions.
How many people work for Rocket Pharmaceuticals?
Latest data suggests 91 work at Rocket Pharmaceuticals.
When does the fiscal year end for Rocket Pharmaceuticals?
Rocket Pharmaceuticals's fiscal year ends in December.
Where is Rocket Pharmaceuticals based?
Rocket Pharmaceuticals's address is: 9 Cedarbrook Drive, Cranbury, NJ, United States, 08512
What is Rocket Pharmaceuticals's ISIN number?
Rocket Pharmaceuticals's international securities identification number is: US77313F1066
What is Rocket Pharmaceuticals's CUSIP number?
Rocket Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 45780V102

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site